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t has long been known that the newly established endo-
helium within and adjacent to bare-metal stents (BMS) is
ot normal. As a response to healing after the barotrauma of
alloon angioplasty alone (1,2), the newly seeded endothe-
ial cells are dysfunctional and remain so for variable periods
f time. Endothelial dysfunction is even more severe after
etal stent implantation. The paradoxical vasoconstrictor
ffects of neurohumoral stimulation are the measurable
ross marker of endothelial dysfunction, the consequences
f which can be devastating. Abnormal endothelial cells
ave a thrombogenic surface, promoting adherence of var-
ous circulating monocytes and platelets and facilitating
latelet aggregation, leukocyte infiltration, and vascular
mooth muscle proliferation. It has been the hope, but not
he reality, that the new endothelium covering drug-eluting
tents (DES) would be more functional and that restoration
f coronary flow would likewise limit endothelial dysfunc-
ion. In this issue of JACC: Cardiovascular Interventions,
im et al. (3), as have others (4,5), continue to demonstrate
he opposite.
See page 65
Kim et al. (3) examined endothelial function 6 months
fter the implantation of sirolimus-eluting stents (SES) and
aclitaxel-eluting stents (PES). In 39 patients with SES, 36
atients with PES, and 10 patients with BMS, left anterior
escending coronary artery vasoconstrictor responses after
ncremental acetylcholine infusions were measured.
ndothelial-independent function was assessed with nitrate
asodilatory responses. Quantitative angiographic vessel
egment diameter changes demonstrated greater vasocon-
Editorials published in the JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-s
ions or the American College of Cardiology.
From the Division of Cardiology, University of California, Irvine.triction to acetylcholine in both SES and PES than in
MS patients. There was no difference between SES and
ES responses. Interestingly, the DES vasoconstrictor re-
ponses were more prominent in the distal than in the
roximal vessel segments.
The limitations of the study by Kim et al. (3) were few.
he underlying degree of endothelial dysfunction in a
oninstrumented artery was similar for the unstented vessel
egments remote from the stent site. Kim et al. (3) used a
olus incremental acetylcholine dose administration,
hereas others have used continuous infusions and pacing-
nduced or exercise-induced coronary vasomotor changes.
hese methods are not identical but should not impact the
onsistent differences observed for the endothelial func-
ional responses. In addition, only patients from Korea were
tudied. Although the sensitivity to acetylcholine may differ
mong well-defined ethnic populations, the endothelial
unctional response certainly can be generalized to most
ther patients. Unlike Kim et al. (3), Togni et al. (4)
eported paradoxical exercise-induced vasoconstriction after
ES in both proximal and distal segments. Nonetheless,
oth Kim et al. (3) and Togni et al. (4) found endothelial
ysfunction was greater in the DES groups than in the
MS groups. Persistent (6 months) endothelial dysfunc-
ion, in addition to its attendant adverse consequences
elated to paradoxical vasoconstriction (more ischemia),
ndothelial cell surface activation (late thrombosis), and
educed collateral function (more severe ischemia insult
fter acute thrombosis), is another of the continuing costs
e pay to reduce in-stent restenosis.
As Kim et al. (3) demonstrate, the increased potential for
dverse clinical events associated with the ubiquitous pa-
hology of endothelial dysfunction forces us to explore
lternatives to the antiproliferative drug approach to reste-
osis. In vitro studies have shown both rampamycin and
aclitaxel are toxic to endothelial cells. Limiting the toxicity
ould impact distant endothelial cells downstream from the
mplantation site. Reducing drug penetration into the local
ascular wall and vaso vasorum may favorably influence
istal regional endothelial cell turnover and function. That
he antiproliferative drugs likely play a negative role on
istal vasculature is deduced from the response in BMS and
ngioplasty groups, as well as from studies involving dimin-
shed collateral function studied late after DES (6).
The future lies in delivery of new endothelial growth
actors, endothelial cell seeding, and the ability to attract
ndothelial progenitor cells to the injured and adjacent areas
o restore endothelial function (7–9). Endothelial progeni-
or cells (EPCs) may be attracted by antibodies coated onto
oronary stents. Current investigation into this process is
nderway (10). This approach might lead to improved
ndothelial cell growth and function in the absence of
oxins, and the reduction of a thrombotic milieu, vasocon-
triction, and acute or subacute stent thrombosis. Exactly
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73ow to deliver or attract EPCs or whether EPCs and their
ffspring will reverse or improve endothelial dysfunction in
atients with diffuse atherosclerosis is unknown at this time.
In light of studies linking the exaggerated endothelial
ysfunction with an excess of adverse clinical events (11), we
hould be especially vigilant in following those patients with
he potential problems noted for DES physiology. Kim et
l. (3) present us with another downside of DES that must
e weighed in the consideration of implantation of this
mportant therapeutic advance for our patients with coro-
ary artery disease.
eprint requests and correspondence: Dr. Morton J. Kern,
ivision of Cardiology, University of California, Irvine, Building
3, Route 81, Room 100, 101 The City Drive, Orange, California
2868-4080. E-mail: mkern@uci.edu.
EFERENCES
1. Van Beusekom HMM, Whelan DM, Hofma SH, et al. Long-term
endothelial dysfunction is more pronounced after stenting than after
balloon angioplasty in porcine coronary arteries. J Am Coll Cardiol
1998;32:1109–17.
2. Caramori PRA, Lima VC, Seidelin PH, Newton GE, Parker JD,
Adelman AA. Long-term endothelial dysfunction after coronary artery
stenting. J Am Coll Cardiol 1999;34:1675–9.3. Kim JW, Suh SY, Choi CU, et al. Six-month comparison of coronary
endothelial dysfunction associated with sirolimus-eluting stent versus
paclitaxel-eluting stent. J Am Coll Cardiol Intv 2008;1:65–71.
4. Togni M, Windecker S, Cocchia R, et al. Sirolimus-eluting stents
associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol
2005;46:231–6.
5. Obata J, Kitta Y, Takano H, et al. Sirolimus-eluting stent implantation
aggravates endothelial vasomotor dysfunction in the infarct-related
coronary artery in patients with acute myocardial infarction. J Am Coll
Cardiol 2007;50:1305–9.
6. Meier P, Zbinden R, Togni M, et al. Coronary collateral function long
after drug-eluting stent implantation. J Am Coll Cardiol 2007;49:
15–20.
7. Kipshidze N, Dangas G, Tsapenko M, et al. Role of endothelium in
modulating neointimal formation. J Am Coll Cardiol 2004;44:
733–9.
8. Roy-Chaudhury P. Endothelial progenitor cells, neointimal hyperpla-
sia, and hemodialysis vascular access dysfunction: novel therapies for a
recalcitrant clinical problem. Circulation 2005;112:3–5.
9. Szmitko PE, Fedak PWM, Weisel RD, Stewart DJ, Kutryk MJB,
Verma S. Endothelial progenitor cells: new hope for a broken heart.
Circulation 2003;107:3093–100.
0. Wojakowski W. Endothelial progenitor cell capture stents—practical
use of cell mobilization. ESC Cardio Website e-Journal Article.
February 27, 2007. Available at: http://www.escardio.org/knowledge/
cardiology_practice/ejournal_vol5/vol5n23.htm. Accessed November
28, 2007.
1. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR,
Lerman A. Long-term follow-up of patients with mild coronary
artery disease and endothelial dysfunction. Circulation 2000;101:
948–54.
